Quanterix (NASDAQ:QTRX) Shares Down 5.7% - Here's What Happened

Key Points

• Shares down 5.7% — Quanterix fell to $3.30 (intraday low $3.27) on Thursday with 731,231 shares traded (about 11% below average) and a market cap of roughly $154.9 million.
• Quarterly results mixed: QTRX reported EPS of ($0.38) vs. consensus ($0.27) (a miss) but revenue of $41.4M beat estimates, while the company shows negative ROE and a -77% net margin and is forecast to post about -0.98 EPS for the year.
• Analyst and institutional picture: The consensus rating is “Reduce” with a $8.00 target despite recent raises to Hold from some firms, and institutions own ~86.48% of the stock after large recent purchases by Millennium, William Blair, Balyasny and others.

Quanterix Corporation (NASDAQ:QTRX - Get Free Report)'s share price fell 5.7% during trading on Thursday . The company traded as low as $3.27 and last traded at $3.30. 731,231 shares traded hands during mid-day trading, a decline of 11% from the average session volume of 818,016 shares. The stock had previously closed at $3.50.

Analyst Ratings Changes

A number of research firms have commented on QTRX. Wall Street Zen raised Quanterix from a "sell" rating to a "hold" rating in a report on Monday, December 29th. Canaccord Genuity Group lifted their price objective on Quanterix from $5.00 to $8.00 and gave the stock a "hold" rating in a report on Monday, December 22nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Quanterix in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Quanterix currently has an average rating of "Reduce" and a consensus target price of $8.00.

Quanterix Stock Down 5.7%

The firm has a fifty day moving average of $5.08 and a 200-day moving average of $5.90. The stock has a market capitalization of $154.90 million, a price-to-earnings ratio of -1.31 and a beta of 1.32.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.11). Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%.The firm had revenue of $41.40 million for the quarter, compared to analyst estimates of $37.95 million. As a group, research analysts forecast that Quanterix Corporation will post -0.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of QTRX. Millennium Management LLC raised its position in shares of Quanterix by 9,880.2% during the 3rd quarter. Millennium Management LLC now owns 1,209,199 shares of the company's stock worth $6,566,000 after purchasing an additional 1,197,083 shares during the last quarter. William Blair Investment Management LLC raised its position in shares of Quanterix by 55.6% during the 4th quarter. William Blair Investment Management LLC now owns 2,046,449 shares of the company's stock worth $13,015,000 after purchasing an additional 731,169 shares during the last quarter. Balyasny Asset Management L.P. raised its position in shares of Quanterix by 1,625.2% during the 2nd quarter. Balyasny Asset Management L.P. now owns 767,801 shares of the company's stock worth $5,106,000 after purchasing an additional 723,295 shares during the last quarter. Portolan Capital Management LLC raised its position in shares of Quanterix by 17.2% during the 3rd quarter. Portolan Capital Management LLC now owns 4,259,851 shares of the company's stock worth $23,131,000 after purchasing an additional 626,229 shares during the last quarter. Finally, Blue Water Life Science Advisors LP raised its position in shares of Quanterix by 157.3% during the 2nd quarter. Blue Water Life Science Advisors LP now owns 957,747 shares of the company's stock worth $6,369,000 after purchasing an additional 585,572 shares during the last quarter. 86.48% of the stock is currently owned by institutional investors and hedge funds.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company's core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.